These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 38990186)

  • 1. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.
    Kamaraj R; Ghosh S; Das S; Sen S; Kumar P; Majumdar M; Dasgupta R; Mukherjee S; Das S; Ghose I; Pavek P; Raja Karuppiah MP; Chuturgoon AA; Anand K
    Bioconjug Chem; 2024 Aug; 35(8):1089-1115. PubMed ID: 38990186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
    Zhang R; Xie S; Ran J; Li T
    J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to targeted protein degradation technologies in drug discovery.
    Xue Y; Bolinger AA; Zhou J
    Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Protein Degradation through E2 Recruitment.
    Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
    ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
    Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
    Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Protein Degradation via Lysosomes.
    Paudel RR; Lu D; Roy Chowdhury S; Monroy EY; Wang J
    Biochemistry; 2023 Feb; 62(3):564-579. PubMed ID: 36130224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in dual PROTACs degrader strategies for disease treatment.
    Liu J; Liu Y; Tang J; Gong Q; Yan G; Fan H; Zhang X; Pu C
    Eur J Med Chem; 2024 Dec; 279():116901. PubMed ID: 39341095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC targeted protein degraders: the past is prologue.
    Békés M; Langley DR; Crews CM
    Nat Rev Drug Discov; 2022 Mar; 21(3):181-200. PubMed ID: 35042991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
    Nalawansha DA; Crews CM
    Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.